Create Account | Sign In: Author or Forum

Search Symptoms

Category: Internal Medicine | Neurology | Oncology | Pathology | Pediatrics | Journal

Back to Journal Articles

Study Assesses Survival After Second Primary Neoplasms

Last Updated: October 09, 2009.

In survivors of childhood cancer, survival following second primary glioma is poor, though the outlook is good for second primary meningioma, according to research published online Sept. 28 in the Journal of Clinical Oncology.

FRIDAY, Oct. 9 (HealthDay News) -- In survivors of childhood cancer, survival following second primary glioma is poor, though the outlook is good for second primary meningioma, according to research published online Sept. 28 in the Journal of Clinical Oncology.

Aliki J. Taylor, M.D., of the University of Birmingham in the United Kingdom, and colleagues analyzed data from 17,980 subjects who had survived at least five years after diagnosis of childhood cancer. Participants had 247 second primary brain or spinal cord neoplasms (SPNs), including 137 meningiomas and 73 gliomas.

The researchers found that five-year relative survival of gliomas was 19.5 percent in males and females, and five-year relative survival of meningiomas was 84 percent in males and 81.7 percent in females. Factors associated with mortality rate after a meningioma included grade and meningioma-associated genetic syndromes; grade also affected survival with gliomas.

"Increasing awareness of the risk of SPNs should lead to use of interventions aimed at reducing risk, for example, reducing radiation dose and treated volume where possible for treatment of FPNs [first primary neoplasms]. For young children with low-grade gliomas, the use of radiotherapy may be delayed or possibly avoided by use of chemotherapy. There is increasing interest in the use of proton therapy to try to reduce the risk of SPNs," the authors write.

Abstract
Full Text (subscription or payment may be required)


Previous: Cardiac Rehabilitation Underused but Beneficial Next: Vaccinating Boys for HPV Is Not Found to Be Cost Effective

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: